The Technical Analyst
Checkmate [CMPI]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Checkmate Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $10.50
America/New_York / 31 des 1970 @ 19:00
| RATING 2022-06-09 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.85 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.65x |
| Company: PE -3.85 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 10.21 - 10.79 ( +/- 2.77%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-05-31 | Powell Michael | Sell | 30 000 | Stock Option (Right to Buy) |
| 2022-05-31 | Powell Michael | Sell | 10 030 | Stock Option (Right to Buy) |
| 2022-05-31 | Powell Michael | Sell | 30 000 | Stock Option (Right to Buy) |
| 2022-05-31 | Flaherty Keith T. | Sell | 10 030 | Stock Option (Right to Buy) |
| 2022-05-31 | Flaherty Keith T. | Sell | 4 012 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| -100.00 |
| Last 90 transactions |
| Buy: 10 162 192 | Sell: 69 692 426 |
Forecast:
01:40 - $9.85
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $10.50 (0.00% ) |
| Volume | 0.0637 mill |
| Avg. Vol. | 0.233 mill |
| % of Avg. Vol | 27.32 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CMPI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CMPI
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. As of May 27, 2022, Checkmate Pharmaceuticals, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.
Latest Press Releases
2022-06-02 01:00:00 - Press Release
Kuros Biosciences: Completion Of The Acquisition Of Checkmate Pharmaceuticals By Regeneron Pharmaceuticals Triggers A $5 Million Milestone Payment
Ad-hoc announcement pursuant to article 53 of the six listing rules
2022-05-17 10:41:00 - Press Release
Checkmate Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Checkmate Pharmaceuticals, Inc. - Cmpi
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of checkmate pharmaceuticals, inc. (nasdaqgm: cmpi) to regeneron pharmaceuticals, inc. (nasdaqgs: regn). under the terms of the proposed transaction, shareholders of checkmate will receive only $10.50 in cash for each share of checkmate that they own. ksf is seeking to determine whether this consideration and the
2022-05-05 19:02:00 - Press Release
Checkmate Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Checkmate Pharmaceuticals, Inc. - Cmpi
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of checkmate pharmaceuticals, inc. (nasdaqgm: cmpi) to regeneron pharmaceuticals, inc. (nasdaqgs: regn). under the terms of the proposed transaction, shareholders of checkmate will receive only $10.50 in cash for each share of checkmate that they own. ksf is seeking to determine whether this consideration and the
2022-04-26 09:00:00 - Press Release
Shareholder Investigation: Halper Sadeh Llp Investigates Psb, Fsi, Twtr
New york , april 26, 2022 /prnewswire/ -- halper sadeh llp, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: ps business parks, inc. (nyse: psb)'s sale to affiliates of blackstone real estate for $187.50 per share in cash. if you are a ps business parks shareholder, click here to learn more about your rights and options.
2022-04-20 10:03:00 - Press Release
Shareholder Alert: Rigrodsky Law, P.a. Is Investigating Checkmate Pharmaceuticals, Inc. Buyout
Wilmington, delaware--(newsfile corp. - april 20, 2022) - rigrodsky law, p.a. is investigating checkmate pharmaceuticals, inc. ("checkmate") (nasdaq: cmpi) regarding possible breaches of fiduciary duties and other violations of law related to checkmate's agreement to be acquired by regeneron pharmaceuticals, inc. (nasdaq: regn). under the terms of the agreement, checkmate's shareholders will receive $10.50 in cash for each share of checkmate common stock they own.to learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-checkmate-pharmaceuticals-inc.to...
Latest News
2022-04-19 14:58:00 - The Motley Fool
Why Checkmate Pharmaceuticals Stock Is Rocketing Higher Today
Checkpoint Pharmaceuticals lands a premium-rich buyout offer from biotech heavyweight Regeneron.
2022-04-19 12:57:59 - InvestorPlace
Why Is Checkmate Pharmaceuticals (CMPI) Stock Up 300% Today?
Checkmate Pharmaceuticals (CMPI) stock is rocketing higher on Tuesday following news that Regeneron Pharmaceuticals (REGN) is acquiring it. The post Why Is Checkmate Pharmaceuticals (CMPI) Stock Up 300% Today?
2022-04-19 09:13:04 - Benzinga
Why Checkmate Pharmaceuticals Shares Are Skyrocketing
Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) shares are trading higher by 328.40% to $10.41 during Tuesday's pre-market session after Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced a deal to acquire the company for $10.50 per share in cash. Checkmate's lead investigational candidate.
2022-04-19 09:13:03 - Benzinga
Checkmate Pharma Shares Skyrocket Over 300% On Regeneron $250M Acquisition Deal
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) will acquire Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) for $10.50 per share, equivalent to a total equity value of approximately $250 million. Checkmate is a clinical-stage biopharmaceutical company focused on proprietary.
2022-04-19 09:11:57 - PennyStocks
Hot Penny Stocks to Buy? 3 to Watch As CMPI Stock Shoots Up 320%
Here's what you need to know about trading penny stocks on April 19th The post Hot Penny Stocks to Buy? 3 to Watch As CMPI Stock Shoots Up 320% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-03-10 17:30:35 - GuruFocus
Investors Hoping for News at Cancer Meeting That Will Boost Share Prices
Given that developing biotechnology companies are more susceptible to swings in stock price than established ones, investors might want to keep an eye on happenings at next month's American Association for Cancer Research Annual Meeting in New Orleans. Of the eight public companies that will discuss clinical trial results, half qualify as small caps or lesser.
2022-03-08 16:30:00 - GlobeNewsWire
Checkmate Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting
CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that it will present biomarker data at the 2022 American Association for Cancer Research (AACR) Annual Meeting taking place in New Orleans, Louisiana from April 8-13, 2022. An e-poster will be made available online starting Friday, April 8 at 1:00pm ET.
2022-01-03 16:30:00 - GlobeNewsWire
Checkmate Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Alan Fuhrman, Interim CEO and President, will present at the H.C. Wainwright BioConnect Virtual Conference being held on January 10-13, 2022. The pre-recorded webcast will be available on-demand starting on Monday, January 10 at 7:00am ET. Checkmate will also host 1x1 investor meetings during the conference.
2021-11-15 16:30:00 - GlobeNewsWire
Checkmate Pharmaceuticals to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Alan Fuhrman, Interim CEO and President, will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference. The pre-recorded webcast will be available on-demand beginning on Monday, November 22 at 10:00am ET through Thursday, December 2, 2021. Checkmate will also host 1x1 investor meetings during the conference.
2021-11-11 16:30:00 - GlobeNewsWire
Checkmate Pharmaceuticals to Present at the Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that James Wooldridge, MD, Chief Medical Officer, will present virtually at the Jefferies London Healthcare Conference taking place November 16-19, 2021. The pre-recorded webcast will be available on-demand beginning on Thursday, November 18 at 3:00am ET through Friday, November 19 at 12:00pm ET. Checkmate will also host 1x1 investor meetings during the conference.